L A Averbukh - JoVE Visualize

Showing results (1-10 of 9) with videos related to

Pageof 1

Sort By:

Antibiotiki|February 1, 1976

[Study using the probit-analysis method of the process of increasing resistance to dipin and bruneomycin in Fisher L-5178 lymphadenosis cells in experiments on animals]L A Averbukh

Antibiotiki|April 1, 1975

[Development of resistance in Fisher lymphadenosis cells to dipin and bruneomycin when these preparations are used separately and in combination]L A Averbukh

Antibiotiki|December 1, 1977

[Development of bruneomycin and rubomycin resistance in mouse lymphadenosis tumor cells and Staphyloccus when these preparations are used separately or together]L A Averbukh

Antibiotiki|October 1, 1976

[Cross resistance in tumor cells and staphylococci with respect to anthracycline-group antineoplastic antibiotics]V A Shorin, L A Averbukh

Antibiotiki|November 1, 1976

[Antitumor activity of carminomycin antibiotic used orally]V A Shorin, V S Bazhanov, L A Averbukh

Antibiotiki|January 1, 1977

[Antitumor activity of the components of a carminomycin complex]V A Shorin, V S Bazhanov, L A Averbukh

Antibiotiki|November 1, 1981

[Synthesis of rubomycin 13-tert-butoxycarbonylhydrazone and the study of its antitumor action]L S Povarov, L E Gol'dberg, V S Bazhanov, et al.

Antibiotiki|February 1, 1983

[Synthesis and antitumor properties of carminomycin 13-cyclohexylidenhydrazone]L S Povarov, V S Bazhanov, L A Averbukh, et al.

Antibiotiki|September 1, 1978

[Effect of microbial and tumor cell adaptation to rubomycin on their uptake of rubomycin and carminomycin]L N Ostanina, L A Averbukh, V L Karpov, et al.

Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:

Pageof 1

Antibiotiki|February 1, 1976

[Study using the probit-analysis method of the process of increasing resistance to dipin and bruneomycin in Fisher L-5178 lymphadenosis cells in experiments on animals]L A Averbukh

Antibiotiki|April 1, 1975

[Development of resistance in Fisher lymphadenosis cells to dipin and bruneomycin when these preparations are used separately and in combination]L A Averbukh

Antibiotiki|December 1, 1977

[Development of bruneomycin and rubomycin resistance in mouse lymphadenosis tumor cells and Staphyloccus when these preparations are used separately or together]L A Averbukh

Antibiotiki|October 1, 1976

[Cross resistance in tumor cells and staphylococci with respect to anthracycline-group antineoplastic antibiotics]V A Shorin, L A Averbukh

Antibiotiki|November 1, 1976

[Antitumor activity of carminomycin antibiotic used orally]V A Shorin, V S Bazhanov, L A Averbukh

Antibiotiki|January 1, 1977

[Antitumor activity of the components of a carminomycin complex]V A Shorin, V S Bazhanov, L A Averbukh

Antibiotiki|November 1, 1981

[Synthesis of rubomycin 13-tert-butoxycarbonylhydrazone and the study of its antitumor action]L S Povarov, L E Gol'dberg, V S Bazhanov, et al.

Antibiotiki|February 1, 1983

[Synthesis and antitumor properties of carminomycin 13-cyclohexylidenhydrazone]L S Povarov, V S Bazhanov, L A Averbukh, et al.

Antibiotiki|September 1, 1978

[Effect of microbial and tumor cell adaptation to rubomycin on their uptake of rubomycin and carminomycin]L N Ostanina, L A Averbukh, V L Karpov, et al.

Pageof 1